GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss
Diabetes · 01.10.2024 · 73 (10) · 1605-1614
DOI: 10.2337/db23-0972 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 08.07.2024. Verfasst von Giuseppe Della Pepa und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Research Council, Institute of Clinical Physiology, Pisa, Italy. Hauptthemen laut MEDLINE: Postprandial Period, Exenatide, Weight Loss, Lipidomics. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Amylin Pharmaceuticals, Bristol-Myers Squibb and AstraZeneca, European Union's Horizon 2020 Research and Innovation Programme under the Marie SkÅ'odowska-Curie for the project “FOIE GRAS: Bioenergetic Remodeling in the…, Horizon 2020 Research and Innovation Programme for the project “Stratification of Obesity Phenotypes to Optimize Future Obesity Therapyâ€?.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Treatment with glucagon-like peptide 1 receptor agonists reduces liver steatosis and cardiometabolic risk (CMR). Few data are available on lipid metabolism, and no information is available on the postprandial lipidomic profile. Thus, we investigated how exenatide treatment changes lipid metabolism and composition during fasting and after a mixed-meal tolerance test (MMTT) in adults with severe obesity without diabetes. Thirty individuals (26 females and 4 males, 30–60 years old, BMI >40 kg/m2, HbA1c 5.76%) were assigned (1:1) to diet with exenatide 10 μg twice daily treatment (n = 15) or without treatment as control (n = 15) for 3 months. Fasting and postprandial lipidomic profile (by liquid chromatography quadrupole time-of-flight mass spectrometry) and fatty acid metabolism (following a 6-h MMTT/tracer study) and composition (by gas chromatography-mass spectrometry) were evaluated before and after treatment. Both groups had slight weight loss (−5.5% vs. −1.9%, exenatide vs. control; P = 0.052). During fasting, exenatide, compared with control, reduced some ceramides (CERs) and lysophosphatidylcholines (LPCs) previously associated with CMR, while relatively increasing unsaturated phospholipid species (phosphatidylcholine [PC], LPC) with protective effects on CMR, although concentrations of total lipid species were unchanged. During MMTT, both groups showed suppressed lipolysis equal to baseline, but exenatide significantly lowered free fatty acid clearance and postprandial triacyclglycerol (TAG) concentrations, particularly saturated TAGs with 44–54 carbons. Exenatide also reduced some postprandial CERs, PCs, and LPCs previously linked to CMR. These changes in lipidomic profile remained statistically significant after adjusting for weight loss. Exenatide improved fasting and postprandial lipidomic profiles associated with CMR mainly by reducing saturated postprandial TAGs and CERs independently of weight loss and diabetes. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Research Council, Institute of Clinical Physiology, Pisa, Italy.
- Sant'Anna School of Advanced Studies, Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Pere Virgili Institute for Health Research, Terragona, Spain.
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Giuseppe Della Pepa, Ele Ferrannini, Amalia Gastaldelli
Förderung
- Amylin Pharmaceuticals, Bristol-Myers Squibb and AstraZeneca
- European Union's Horizon 2020 Research and Innovation Programme under the Marie SkÅ'odowska-Curie for the project “FOIE GRAS: Bioenergetic Remodeling in the…
- Horizon 2020 Research and Innovation Programme for the project “Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy�
- European Union’s Horizon Europe Research and Innovation Programme for the project PAS GRAS: De-risking metabolic, environmental and behavioral determinants o…
Zitieren
APA
Della Pepa, G., Patrício, B. G., Carli, F., Sabatini, S., Astiarraga, B., Ferrannini, E., Camastra, S., & Gastaldelli, A. (2024). GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss. Diabetes, 73(10), 1605-1614. https://doi.org/10.2337/db23-0972
Vancouver
Della Pepa G, Patrício BG, Carli F, Sabatini S, Astiarraga B, Ferrannini E, et al. GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss. Diabetes. 2024;73(10):1605-1614. doi:10.2337/db23-0972
BibTeX
@article{DellaPepa2024,
author = {Della Pepa, Giuseppe and Patrício, Bárbara G and Carli, Fabrizia and Sabatini, Silvia and Astiarraga, Brenno and Ferrannini, Ele and Camastra, Stefania and Gastaldelli, Amalia},
title = {GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss},
journal = {Diabetes},
year = {2024},
volume = {73},
number = {10},
pages = {1605--1614},
doi = {10.2337/db23-0972}
}
EUVIMED